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Poor pharmacological adherence (adherence) is a problem that
reduces quality of life in patients with chronic diseases and leads
to wastage of health care resources.1,2 Few comparative studies of
adherence to inhaled and oral medicines have been performed in
Japanese patients with asthma and chronic obstructive pulmonary
disease (COPD).3,4 To investigate adherence levels to inhaled med-
icines, a multicenter, cross-sectional non-interventional trial was
conducted in Japanese patients who had regular use of both inhaled
and oral medicines for asthma or COPD by the Kyushu Asthma
Seminar Investigator Group, which was approved by each local
ethics board (UMIN No. R000015329) (Supplementary Material:
Table 1).
To investigate adherence in consecutive outpatients with
asthma (aged 20 and <80 years) and COPD (aged 40 and <80
years) who were taking at least one regular prescribed inhaled
and oral medication without changes in regimens for >6 months
(Supplementary Material: Table 2), one inhaled and one oral med-
icine were selected as the most important among all regular pre-
scribed medicines [mean (±standard deviation) was the number
of different inhaled devices and oral medicines
(range) ¼ 1.1 ± 0.4 (1e3) and 4.3 ± 3.0 (1e18) available to patients
with asthma; 1.5 ± 0.5 (1e3) and 5.0 ± 4.1 (1e22) in patients with
COPD, respectively] by each physician without consultation with
the patient (Supplementary Material). Adherence levels were
examined by questionnaire and prescription reﬁll method. The
characteristics and lung function data within 6 months of patients
were obtained after written consent (see Supplementary Material
for deﬁnition and control levels of asthma and COPD). Poor adher-
ence to medicines was deﬁned on the basis of <80% adherence to
selected inhaled or oral medicines by either the questionnaire or
prescription reﬁll method.5,6 We statistically compared the popula-
tions of patients with poor adherence to selected inhaled and oral
medicines, and calculated the odds ratios [95% conﬁdential interval
(CI)] of poor adherence to inhaled medicines in total patients
(asthma and COPD), patients with asthma, and patients with
COPD by using a Fisher's exact tests. By univariate and multivariate
analyses, we investigated the risk factors as patient-, social-, and
treatment-related factors [odds ratios (95% CI)] for poor adherence
to inhaled medicines to compare patients with and without poorPeer review under responsibility of Japanese Society of Allergology.
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p < 0.05 were considered signiﬁcant. Statistical analyses were per-
formed using software package JMP version 9.0® (SAS Institute
Japan Inc., Tokyo, Japan).
Of the 479 patients who provided informed consent, 372 (num-
ber of patients with Asthma-COPD overlap ¼ 9) [248 (5) with
asthma and 124 (4) with COPD] patients were part of the ﬁnal anal-
ysis, and the numbers of total patients with and without poor
adherence to inhaled medicines were 62 and 310, respectively
(Supplementary Material: Fig. 1 and Table 3). Figure 1 shows that
the population of patients with poor adherence to inhaled medi-
cines was signiﬁcantly higher than that of patients with poor
adherence to oral medicines in total patients (odds ratio: 8.0 [95%
CI: 3.8e17.0] p < 0.0001), patients with asthma (10.2 [3.9e26.5]
p < 0.0001), and patients with COPD (5.0 [1.4e18.0] p ¼ 0.0156).
Table 1 shows that the independent risk factors for poor adherence
to inhaled medicines included a poor compliance rate between
scheduled appointments and clinic visits as social-related factors
in total patients, once inhalation per administration as treatment-
related factors in total patients and patients with asthma, and the
regular usage of any nasal sprays as treatment-related factors in pa-
tients with COPD. However, the types of compounds such as
inhaled corticosteroids, b2-agonist and muscarinic receptor antag-
onist and devices such as pressurized metered-dose inhaler, dry
powder inhaler and soft mist inhaler were not signiﬁcantly associ-
ated with any adherence levels to inhaled medicines in patients
with asthma and COPD (full analysis is shown in Supplementary
Material: Table 4).
To our knowledge, our study is the ﬁrst study in which adher-
ence levels between inhaled and oral medicines are compared,
and the feature of poor adherence to only inhaled medicines is
investigated in Japanese patients with asthma and COPD. We
found that the adherence levels to selected inhaled medicines
were signiﬁcantly poorer than that to oral medicines in all pa-
tients, patients with asthma, and patients with COPD. However,
our study demonstrated that the population of patients with
good adherence to selected inhaled (>75%) and oral (>90%) medi-
cations was higher than that of patients in other countries with
chronic diseases such as hypertension, diabetes, and asthma.1,5
The difference is still unclear; however, it may be associated
with local behaviors or differences in the health care system
among countries or areas. A compliance rate for the clinic visit is
associated with a relationship between patients and physicians
and is considered a social-related factor.7,8 In our study, thevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1. Comparison of the population of patients with poor and good adherence between inhaled and oral medicines in total patients, patients with asthma, and patients with COPD
by either questionnaire or prescription reﬁll methods.
Table 1
Risk factors for patients with poor adherence to only selected inhaled medicines in patients with asthma and COPD by univariate and multivariate analysis.
Characteristicsy
Univariate analysis Multivariate analysis
Poor adherence to only inhaled medicinesz Odds ratio
(95% CI)
p Values Odds ratio
(95% CI)
p Values
With n/N Without n/N
Total patients
>23.0 kg/m2 of body mass index 35/62 148/310 1.4 (0.8e2.5) 0.2 e e
Poor attention to detail in personality 14/62 34/309 2.4 (1.2e4.7) 0.0210 1.3 (0.5e3.0) 0.6
Poor compliance rate between
scheduled appointments and clinic visits
8/60 7/305 6.6 (2.3e18.3) 0.0009 4.9 (1.4e18.7) 0.0144
Once inhalation per administration in
selected inhaled medicines
49/62 197/310 2.2 (1.1e4.2) 0.0189 2.0 (1.0e4.0) 0.0377
Asthma
Poor attention to detail in personality 12/41 26/180 2.9 (1.3e6.3) 0.0153 1.7 (0.6e4.4) 0.3
Poor compliance rate between scheduled
appointments and clinic visits
6/39 6/202 5.9 (1.8e19.5) 0.0055 3.8 (0.9e16.7) 0.1
Once inhalation per administration
in selected inhaled medicines
39/41 139/207 9.5 (2.2e40.7) <0.0001 8.7 (2.5e54.8) 0.0001
COPD
Regular usage of any nasal sprays in all medicines 5/21 5/103 6.1 (1.6e23.6) 0.0125 4.4 (1.0e18.6) 0.0460
>1 time of administrations per day
in selected inhaled medicines
9/21 19/103 3.3 (1.2e9.0) 0.0220 2.5 (0.8e7.3) 0.1
CI, conﬁdence interval.
y Themedianwas used as cut-off value between high and low. Themedian of bodymass index in total patients was 23.0 kg/m2, numbers of inhalations per administration in
selected inhaled medicines in total patients and patients with asthma was 1 inhalation, and time of administrations per day in selected inhaled medicines in patients with
COPD was 1 time.
z The number of patients with positive results in each characteristics/number of total patients with and without poor adherence to only inhaled medicines was expressed as
n/N. The number of patients who did not report regarding characteristics of personality was 1 (1 with asthma) and the compliance rate between scheduled appointments and
clinic visits was 7 (7 with asthma).
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rate may visit a clinic without forfeits and discriminations. Previ-
ous reviews showed that complex regimens were associated
with poor adherence and are considered treatment-related fac-
tors.7,8 We considered that poor adherence to only inhaled, not
oral, medicines may be associated with the complexity of device
usage. We found that fewer numbers of inhalations (once inhala-
tion per administration) of selected inhaled medicines was an in-
dependent risk factor for poor adherence to only selected
inhaled medicines rather than twice or more inhalations per
administration in total patients and patients with asthma. For pa-
tients with poor adherence, respiratory physicians have a ten-
dency to change medication regimens to make it easier to take,
such as less frequency of administration, which may have led to
the correlation between fewer numbers of inhalations per admin-
istration and poorer adherence observed in our study. However,
we do not have data to conﬁrm this. In patients with COPD, those
with the regular usage of any nasal sprays had a signiﬁcantly
higher population of patients with poor adherence to only selected
inhaled medicines than patients who did not use nasal spray,
although the population was small (8%). It was not clear whether
the regular usage of any nasal sprays was associated with poorPlease cite this article in press as: Imamura Y, et al., Poor pharmacologic
Japanese patients with asthma and chronic obstructive pulmonary d
j.alit.2016.10.008adherence to inhaled medicines in patients with COPD. Further
studies are necessary to clarify the issue.
Our study had some limitations. First, the collected data were
based on interviews and not on direct methods.5,9,10 Second, selec-
tion of only one medicine from inhaled and oral medication groups
may have led to a selection bias in our results. Third, a patient's
knowledge of taking medications at a ﬁxed time and accuracy of
inhalation technique were not investigated. We did not have ob-
servers that evaluated adherence and technique. Fourth, the efﬁ-
cacy and safety of inhaled and oral medicines were not
compared. Fifth, the sample size of COPD patients (n ¼ 124) may
be statistically small (Supplementary Material). Sixth, we did not
investigate if the factors of airway reversibility to bronchodilators
were associated with poor adherence levels to inhaled medicines.
Seventh, we could not address why there were fewer inhalations
of inhaled medicine in patients with asthma and the regular usage
of any nasal sprays in patients with COPD was an independent risk
factor for poor adherence to inhaled medicines. Further studies are
necessary to clarify these limitations.
In conclusion, we believe that our results will contribute to
improved education and management of patients that use inhaled
medicines.al adherence to inhaled medicines compared with oral medicines in
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